Last updated on June 2018

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome


Brief description of study

An Open-Label Study of Volanesorsen (IONIS 304801) Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Detailed Study Description

This is a multi-center, open-label study for Group 1: ISIS 304801-CS6 (index study) roll-over FCS patients, Group 2: ISIS 304801-CS16 (index study) roll-over FCS patients, and Group 3: FCS patients who did not participate in the ISIS 304801-CS6 or ISIS 304801-CS16 index studies. All patients will receive volanesorsen 300 mg once per week for 52 weeks. Patients will have the option of continuing dosing for an additional 52 weeks until an expanded access program is approved and available in their country.

Clinical Study Identifier: NCT02658175

Contact Investigators or Research Sites near you

Start Over

Patient Advocacy

IONIS Investigative Site
Huntington Beach, CA United States

Patient Advocacy

IONIS Investigative Site
San Francisco, CA United States

Patient Advocacy

IONIS Investigative Site
Boca Raton, FL United States

Patient Advocacy

IONIS Investigative Site
Boston, MA United States

Patient Advocacy

IONIS Investigative Site
Philadelphia, PA United States

Patient Advocacy

IONIS Investigative Site
Houston, TX United States

Patient Advocacy

IONIS Investigative Site
Norfolk, VA United States

Patient Advocacy

IONIS Investigative Site
Seattle, WA United States

Patient Advocacy

IONIS Investigative Site
Sao Paulo, Brazil

Patient Advocacy

IONIS Investigative Site
Vancouver, BC Canada

Patient Advocacy

IONIS Investigative Site
Chicoutimi, QC Canada

Patient Advocacy

IONIS Investigative Site
Montreal, QC Canada

Patient Advocacy

IONIS Investigative Site
Quebec, QC Canada

Patient Advocacy

IONIS Investigative Site
Paris, France

Patient Advocacy

IONIS Investigative Site
Marseille Cedex 05, France

Patient Advocacy

IONIS Investigative Site
Nantes cedex 1, France

Patient Advocacy

IONIS Investigative Site
Berlin, Germany

Patient Advocacy

IONIS Investigative Site
Safed, Israel

Patient Advocacy

IONIS Investigative Site
Palermo, Italy

Patient Advocacy

IONIS Investigative Site
Roma, Italy

Patient Advocacy

IONIS Investigative Site
Rome, Italy

Patient Advocacy

IONIS Investigative Site
Amsterdam-Zuidoost, Netherlands

Patient Advocacy

IONIS Investigative Site
Cape Town, South Africa

Patient Advocacy

IONIS Investigative Site
Barcelona, Spain

Patient Advocacy

IONIS Investigative Site
La Coruna-Galicia, Spain

Patient Advocacy

IONIS Investigative Site
Madrid, Spain

Patient Advocacy

IONIS Investigative Site
Sevilla, Spain

Patient Advocacy

IONIS Investigative Site
Zaragoza, Spain

Patient Advocacy

IONIS Investigative Site
Birmingham, United Kingdom

Patient Advocacy

IONIS Investigative Site
London, United Kingdom

Patient Advocacy

IONIS Investigative Site
Manchester, United Kingdom